Envoy Technologies Inc
Total Consideration
$35.5M
Purchase-Price Allocation
Goodwill
$30.1M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | -5.00% | -2.40% | -1.30% | 0.20% | -1.20% | -0.10% |
| Foreign Rate Differential | — | — | 4.20% | 3.20% | 1.50% | — |
| Other Adjustments | 1.00% | -0.30% | -11.20% | 2.30% | -5.10% | — |
| Nondeductible Expenses | 0.00% | 1.60% | 4.30% | 1.80% | 2.00% | 3.80% |
| Valuation Allowance Change | 31.00% | 12.80% | -30.80% | 7.30% | 13.50% | -14.90% |
| Tax Law Change | — | — | 0.70% | 0.20% | 0.00% | 2.30% |
| Effective Tax Rate | 0.00% | 0.00% | -0.30% | 0.70% | 0.40% | -0.40% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | — | — | $308.0K | $1.5M | $656.0K | $317.0K |
| Income Taxes Paid (Cash) | — | — | $73.0K | — | $218.0K | $338.0K |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$35.5M
Purchase-Price Allocation
Goodwill
$30.1M
Purchase-Price Allocation
Goodwill
$17.9M
Total Consideration
$3.6M
Purchase-Price Allocation
Goodwill
$1.7M
Purchase-Price Allocation
Goodwill
$1.7M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | +$1M | $982.0K | $268.0K |
| Contract Termination | Contract Termination | +$70.0K | $70.0K | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).